GENinCode has announced its results for the 6-months to June 2021, a period prior to its IPO in July 2021. As per our recent initiation report (7 Sep 2021), the company is progressing its three-part commercialisation strategy, targeting the US, UK, and Europe. In the US, the company remains on track to submit its de novo FDA filing for Cardio inCode in the coming months. Revenues, generated largely from Europe, grew by c45% in the period while the EBITDA loss increased to support commercialisati ....
